Volume 34, No 10, Oct 2024

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 34 Issue 10, October 2024: 679-680

RESEARCH HIGHLIGHTS

All-in-one Hangzhou Protocol: killing four birds with one stone

Haopeng Wang^1,2,3,†,* , Shizhen Qiu^1,4,† , Mohamad Mohty^5,*

¹School of Life Science and Technology, ShanghaiTech University, Shanghai, China
²State Key Laboratory of Advanced Medical Materials and Devices, ShanghaiTech University, Shanghai, China
³Shanghai Clinical Research and Trial Center, Shanghai, China
⁴Department of Hematology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
⁵Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, and INSERM, Saint-Antoine Research Centre, Paris, France
^†These authors contributed equally: Haopeng Wang, Shizhen Qiu
Correspondence: Haopeng Wang(wanghp@shanghaitech.edu.cn)Mohamad Mohty(mohamad.mohty@inserm.fr)

In a recent study published in The New England Journal of Medicine, researchers developed an innovative “all-in-one” treatment protocol that combines CD7 chimeric antigen receptor T-cell therapy with subsequent haploidentical hematopoietic stem cell transplantation. This approach significantly advances the treatment of CD7+ hematological malignancies by eliminating the need for myeloablative chemotherapy and immunosuppressants for graft-versus-host disease prophylaxis.

https://doi.org/10.1038/s41422-024-00983-8

FULL TEXT | PDF

Browse 556